Rofecoxib, a COX-2–specific inhibitor, is known to increase monocyte binding to intracellular adhesion molecule-1 (ICAM-1) with concomitant enhancement of tumor tissue infiltration and restoration of immune function in head and neck cancer patients [17]. This evidence concerns the gene ICAM1 and head and neck cancer.